Sinaptica Therapeutics develops investigational non-invasive neuromodulation systems for Alzheimer’s disease. Its platform is built around the view that Alzheimer’s involves disruption across large-scale brain networks, particularly the default mode network, and positions stimulation as a personalized network-level intervention rather than a fixed-site protocol. Sinaptica remains in clinical-stage development, and SinaptiStim has not received market authorization for sale.

SinaptiStim combines neuronavigated repetitive transcranial magnetic stimulation with EEG-based calibration, MRI-informed targeting, and software-guided personalization. Treatment is centered on the precuneus as a key default mode network hub, with patient-specific parameters derived from structural imaging and neurophysiological response patterns. The platform is best understood as a precision neuromodulation system designed to improve targeting consistency and therapeutic specificity in Alzheimer’s disease.

The system is being developed for supervised clinical use in patients with Alzheimer’s disease, with the goal of slowing cognitive decline through repeated modulation of dysfunctional brain networks. Sinaptica has reported positive Phase 2 results and holds FDA Breakthrough Device designation, placing it within the emerging group of neuromodulation companies pursuing personalized interventions for neurodegenerative disease.